Video Latest - ecancer

Comment: Advances in breast cancer presented at ASCO 2014

Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland

1 Jun 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France

31 May 2014

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Dr John Byrd - The Ohio State University, Columbus, USA

31 May 2014

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France

31 May 2014

Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer

Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA

31 May 2014

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Dr John Byrd - The Ohio State University, Columbus, USA

31 May 2014

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland

20 May 2014

Checkpoint blockade: a concept or already a reality?

Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy

20 May 2014

Emerging pathways in immunotherapy

Prof Christopher Höller - Medical University of Vienna, Vienna, Austria

20 May 2014

Myeloma genomics and Immuno-oncology

Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo

15 May 2014

Novel targets and immune based therapy in myeloma

Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel

15 May 2014

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson

15 May 2014

Video